Clinical Trial Update: Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing UTD2 plus capecitabine to capecitabine alone as adjuvant therapy for patients with non-pCR triple-negative breast cancer; curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• UTD2

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer, TNBC | Phase 3 | Status: NOT_YET_RECRUITING